Pfizer on Friday committed to supply up to 40 million doses of its COVID-19 vaccine this year to a World Health Organization-backed effort to get affordable shots to poor and middle-income countries.
The deal is a boost to the global program known as COVAX, as wealthy nations have snapped up most of the millions of coming shots.
The commitment, announced at a virtual press conference held by the Geneva-based WHO, is seen as important because Pfizer and its partner BioNTech won the first emergency authorization from the influential U.S. Food and Drug Administration in mid-December. That clearance makes it easier for international health groups and poor nations to quickly OK emergency use.
Earlier this week, WHO Director-General Tedros Adhanom Ghebreyesus criticized drugmakers for seeking profits from the pandemic and mostly supplying wealthy countries.
The 40 million doses for a vaccine requiring two doses are a tiny sliver of what’s needed for COVAX, which aims to vaccinate billions of people in 92 low- and middle-income countries.
The global program previously secured access to nearly 2 billion doses of vaccines from five other vaccine producers, plus options on a billion doses more.
New York-based Pfizer Inc. had not previously committed to providing its COVID-19 vaccine to poor countries without making a profit during the pandemic, as a couple rivals have.
However, Pfizer and Germanys BioNTech said they would provide their vaccine to COVAX at an undisclosed not-for-profit price. The companies still must execute a supply agreement covering distribution, but the doses are to be delivered throughout 2021, starting by the end of March.
We share the mission of COVAX and are proud to work together so that developing countries have the same access as the rest of the world, which will bring us another step closer to ending this global pandemic, Pfizer Chief Executive Officer Albert Bourla said in a statement.
Dr. Seth Berkley, CEO of GAVI, the Vaccine Alliance, which is leading procurement and delivery of vaccines for COVAX, called the deal a major step forward for equitable access to vaccines.
Pfizer and BioNTech said they would also help health systems handle the vaccine, which requires ultracold storage.
Many public health officials have expressed skepticism that the Pfizer vaccine could be successfully kept so cold across the globe. Pfizer has been shipping the shots in special containers with dry ice, but even in the U.S. some doses have been thrown out because they weren’t kept at the proper temperature.
Pfizer has said its been ramping up production and expects to be able to make 2 billion doses in 2021, up from its earlier forecast of 1.3 billion doses. That long-term goal comes with a short-term cost: The company is slowing production at its Belgium factory while it makes changes needed to boost production.
___
Follow Linda A. Johnson on Twitter: @LindaJ_onPharma
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News, Breaking News and Coronavirus News here
Comments
0 comment